TOVX — Theriva Biologics Income Statement
0.000.00%
Last trade - 00:00- $3.84m
- -$7.62m
- 18
- 56
- 19
- 21
Annual income statement for Theriva Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 10.2 | 14.3 | 21.6 | 21.4 | 26.3 |
| Operating Profit | -10.2 | -14.3 | -21.6 | -21.4 | -26.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -10.1 | -14.3 | -21.1 | -20 | -25.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.1 | -14.3 | -19.7 | -18.3 | -25.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -10 | -14.3 | -19.7 | -18.3 | -25.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.6 | -23.2 | -20 | -18.3 | -25.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.61 | -1.9 | -1.3 | -1.14 | -13.9 |